Literature DB >> 8004750

Antitumor activity of halogen analogs of phosphoramide, isophosphoramide, and triphosphoramide mustards, the cytotoxic metabolites of cyclophosphamide, ifosfamide, and trofosfamide.

R F Struck1, S M Schmid, W R Waud.   

Abstract

A series of halogen analogs of phosphoramide mustard, isophosphoramide mustard, and triphosphoramide mustard, the cytotoxic metabolites of the antitumor drugs cyclophosphamide, ifosfamide, and trofosfamide, respectively, was evaluated in vitro against human tumor cell lines and in vivo against experimental tumors to investigate the effect of replacement of chlorine with bromine or fluorine on the antitumor activity of the parent phosphoramide mustards. In the experimental tumors L1210 leukemia, B16 melanoma, mammary adenocarcinoma 16/C, and ovarian sarcoma M5076, the antitumor activity of the analogs was observed to be generally comparable with that of the parent mustards when chlorine was replaced by bromine but uniformly lower when chlorine was replaced by fluorine. Furthermore, the monobromo analog of isophosphoramide mustard displayed equal or somewhat greater activity in comparison with cyclophosphamide when evaluated against subcutaneously implanted L1210 leukemia with intraperitoneal drug treatment and against mammary adenocarcinoma 16/C.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8004750     DOI: 10.1007/BF00685076

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  10 in total

1.  Isolation and mass spectral identification of blood metabolites of cyclophosphamide: evidence for phosphoramide mustard as the biologically active metabolite.

Authors:  R F Struck; M C Kirk; M H Witt; W R Laster
Journal:  Biomed Mass Spectrom       Date:  1975-02

Review 2.  Metabolism of oxazaphosphorines.

Authors:  N E Sladek
Journal:  Pharmacol Ther       Date:  1988       Impact factor: 12.310

3.  Experimental evaluation of potential anticancer agents. 28. Effects of therapy on viability and rate of proliferation of leukemic cells in various anatomic sites.

Authors:  H E Skipper; F M Schabel; W S Wilcox; W R Laster; M W Trader; S A Thompson
Journal:  Cancer Chemother Rep       Date:  1965-08

4.  Dechloroethylation of ifosfamide and neurotoxicity.

Authors:  M P Goren; R K Wright; C B Pratt; F E Pell
Journal:  Lancet       Date:  1986-11-22       Impact factor: 79.321

5.  Cyclophosphamide cystitis--identification of acrolein as the causative agent.

Authors:  P J Cox
Journal:  Biochem Pharmacol       Date:  1979-07-01       Impact factor: 5.858

6.  Alkylating properties of phosphoramide mustard.

Authors:  M Colvin; R B Brundrett; M N Kan; I Jardine; C Fenselau
Journal:  Cancer Res       Date:  1976-03       Impact factor: 12.701

7.  Acrolein, the causative factor of urotoxic side-effects of cyclophosphamide, ifosfamide, trofosfamide and sufosfamide.

Authors:  N Brock; J Stekar; J Pohl; U Niemeyer; G Scheffler
Journal:  Arzneimittelforschung       Date:  1979

Review 8.  Ifosfamide.

Authors:  M Zalupski; L H Baker
Journal:  J Natl Cancer Inst       Date:  1988-06-15       Impact factor: 13.506

Review 9.  Oxazaphosphorine cytostatics: past-present-future. Seventh Cain Memorial Award lecture.

Authors:  N Brock
Journal:  Cancer Res       Date:  1989-01-01       Impact factor: 12.701

10.  Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines.

Authors:  D A Scudiero; R H Shoemaker; K D Paull; A Monks; S Tierney; T H Nofziger; M J Currens; D Seniff; M R Boyd
Journal:  Cancer Res       Date:  1988-09-01       Impact factor: 12.701

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.